[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study - PubMed
5 hours ago
- #radioligand therapy
- #immunotherapy
- #prostate cancer
- Study evaluated [177Lu]Lu-PSMA-617 combined with pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC).
- 76% of 37 participants achieved a ≥50% decline in prostate-specific antigen (PSA) with a median follow-up of 30 months.
- Treatment-related adverse events were mostly grade 1-2; grade 3 events included immune-related issues in 30% of participants, with no grade 4 events or deaths.
- Combination therapy showed encouraging activity and manageable toxicity, suggesting durable benefit for a patient subset.